Drug Profile
Research programme: controlled-release therapeutics - Camurus/undiclosed companies
Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Camurus; Unknown
- Class Analgesics; Antineoplastics; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Metabolic disorders; Pain
- Discontinued Endocrine disorders; Viral infections
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Endocrine disorders in Sweden (unspecified route)
- 27 Mar 2023 Discontinued - Preclinical for Viral infections in Sweden (unspecified route)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Endocrine-disorders in Sweden (Controlled release)